White Oaks Mall unveils plans for hotel, new businesses — and staying bus-friendly - London Free Press

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

Canada holds a competitive advantage in Asian LNG markets, benefiting from shorter shipping routes, abundant natural gas, and lower-emission projects. Canada is set to reach 33 million tonnes of annual LNG export capacity by 2030, following LNG Canada's Phase 2 expansion and the addition of Cedar LNG and Woodfibre.

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

The tailored mRNA vaccine is intismeran (or mRNA-4157), which uses a synthetic mRNA that holds the unique genetic coding for up to 34 mutations in a patient’s own cancer cells. To produce the personalized vaccines, researchers compare the genetic sequences of a patient’s cancer cells with those of healthy cells and pick out cancer-specific mutations that could help the immune response selectively target just the cancer cells. In the trial, researchers assessed “recurrence-free survival” or RFS, which is the amount of time a patient has without the cancer returning, and “distant metastasis-free survival” or DMFS, which is the amount of time a patient has without the cancer returning and occurring in a different part of the body than where it began.